The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance (Q43601610)

25 November 2017

The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance (English)

1 reference

25 November 2017

Michael D. B. Swedberg

4

1 reference

25 November 2017

T Rasmussen

1

1 reference

25 November 2017

A Fink-Jensen

2

1 reference

25 November 2017

P Sauerberg

3

1 reference

25 November 2017

C Thomsen

5

1 reference

25 November 2017

M J Sheardown

6

1 reference

25 November 2017

L Jeppesen

7

1 reference

25 November 2017

D O Calligaro

8

1 reference

25 November 2017

N W DeLapp

9

1 reference

25 November 2017

C Whitesitt

10

1 reference

25 November 2017

J S Ward

11

1 reference

25 November 2017

H E Shannon

12

1 reference

25 November 2017

F P Bymaster

13

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

25 November 2017

Schizophrenia Research

1 reference

25 November 2017

49

1 reference

25 November 2017

193-201

1 reference

25 November 2017

1-2

1 reference

Catecholamine regulation of the prefrontal cortex

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane .

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Potential role of muscarinic receptors in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

The mesolimbic system, denervation and the climbing response in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Cholinesterase inhibitors: A new class of psychotropic compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Muscarinic agonists exhibit functional dopamine antagonism in unilaterally 6-OHDA lesioned rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Effects of haloperidol, sulpiride and SCH 23390 on passive avoidance learning in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Antagonism of the hypothermic effect of clozapine in mice by centrally-active alpha 2-adrenergic antagonists and alpha 1-adrenergic agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Synthesis and structural determination of stereoisomers of muscarinic ligands of the (3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicycloalkane type

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Antipsychotic drug doses and neuroleptic/dopamine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Reduction of the scopolamine-induced impairment of passive-avoidance performance by sigma receptor agonist in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

Modulation of memory fields by dopamine D1 receptors in prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900129-8

7 January 2021

10.1016/S0920-9964(00)00129-8

Identifiers

DOI

1 reference

25 November 2017

1 reference